VESUGEN 20 MG

Dragon Pharma Vesugen 20 mg – Synthetic Tripeptide for Vascular Research

Dragon Pharma Vesugen 20 mg is a synthetic tripeptide bioregulator with the amino acid sequence Lys-Glu-Asp (KED). Developed within the well-established Khavinson peptide framework, this compound has been investigated in laboratory settings for its potential effects on vascular endothelial cells, microcirculation, and age-related changes in blood vessel walls.

Each vial contains 20 mg of lyophilized Vesugen in a 2 mL format, requiring reconstitution with bacteriostatic water before use. Vesugen represents a targeted research tool for investigating vascular biology, endothelial function, and the molecular mechanisms underlying vascular aging and microcirculatory health. For related research compounds, explore our peptides category and specifically Cardiogen for complementary cardiovascular research applications.

What Makes Vesugen Valuable in Research?

Vesugen belongs to a class of short-chain peptides known for their tissue-specific bioregulatory properties. The KED sequence has been studied for its ability to influence cellular processes relevant to vascular health, including endothelial cell function, microcirculatory dynamics, and the vascular changes associated with aging. Its defined sequence and mechanism of action make it a practical tool for investigating the molecular basis of vascular regulation.

Researchers value Vesugen for its targeted approach to studying vascular biology. Its ability to modulate endothelial cell activity and microcirculation provides insights into the mechanisms that govern vascular health and age-related vascular changes. For investigators exploring other areas of vascular research, MOTS-C offers complementary research avenues in metabolic and vascular function studies.

Current scientific literature on Khavinson peptides, including Vesugen, can be accessed through the PubMed database, where researchers can review peer-reviewed studies on their biological activity and experimental applications.

Key Research Applications for Dragon Pharma Vesugen

• ✔ Investigation of vascular endothelial cell function
• ✔ Evaluation of microcirculation and blood flow dynamics
• ✔ Research on age-related vascular changes
• ✔ Studies of peptide bioregulation in vascular models
• ✔ Preclinical models of vascular health and aging

Product Details

Dosage & Usage Guidelines

Reconstitution Protocol

• ✔ Use sterile bacteriostatic water for injection
• ✔ Add appropriate volume to achieve desired concentration
• ✔ Swirl gently to dissolve – do not shake vigorously
• ✔ Store reconstituted solution at 2–8°C

Reconstitute the lyophilized powder using bacteriostatic water to a concentration suitable for your research protocol. The 20 mg format allows for flexible dosing across a range of experimental models. Always use aseptic technique during preparation to maintain peptide integrity.

Typical Research Parameters

In research settings, Vesugen is typically administered via subcutaneous or intraperitoneal injection. Dosing schedules and concentrations vary widely depending on the experimental design, animal model, and specific research objectives.

• ✔ Commonly used in vascular endothelial function studies
• ✔ Often combined with histological and molecular analysis
• ✔ Used to investigate microcirculation and vascular aging
• ✔ Research models include vascular aging and microcirculatory paradigms

Factors to Consider in Research Protocols

• Short-chain peptide with specific bioregulatory properties
• Reconstitution stability is limited; prepare fresh solutions for each use
• Individual variation in response may be observed across subjects
• Storage conditions significantly impact peptide stability

Lab Testing & Batch Transparency

Lab status

COA pending release

Third-party analytical testing (COA) for Dragon Pharma Vesugen 20 mg is currently not yet available. Batch-specific assay data, purity analysis, and verification documentation will be published once released.

Testing Status

Pending

COA Availability

Not yet published

Batch Verification

In progress

Update

Coming soon

Transparency note: Dragon Pharma publishes batch-specific lab reports once analytical testing is completed and verified.

Awaiting COA

Shipping & Product Authenticity

What to Expect

• ✔ Orders are processed after payment confirmation
• ✔ USA Domestic shipping is typically faster when local stock is selected
• ✔ International orders include tracking, though update frequency may vary by destination
• ✔ Multiple warehouses may result in separate shipments when applicable

For complete delivery details, tracking policy, and reshipment terms, please see our Shipping Info page.

Storage

Store the lyophilized powder at controlled room temperature (15–25°C) in a dry, dark place, away from direct light and moisture. The unopened vial should be kept in its original packaging to maintain stability.

After reconstitution, store the solution at 2–8°C and use within 14 days. Do not freeze. Discard any unused portion after the recommended storage period. Before use, inspect the solution and avoid use if it appears cloudy, discolored, or contains particulate matter, or if the vial or seal is compromised.

Keep out of reach of children. Follow proper handling and sterile injection practices during research use.

Proper storage conditions help maintain product stability and consistent performance across the product's shelf life.

Frequently Asked Questions